United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - cytarabine (unii: 04079a1rdz) (cytarabine - unii:04079a1rdz) - cytarabine 100 mg in 1 ml - cytarabine injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. it has also been found useful in the treatment of acute non-lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. intrathecal administration of cytarabine injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia. cytarabine injection is contraindicated in those patients who are hypersensitive to the drug.

United States - English - NLM (National Library of Medicine)

mylan institutional llc - cytarabine (unii: 04079a1rdz) (cytarabine - unii:04079a1rdz) - cytarabine 100 mg in 5 ml - cytarabine injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. it has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. intrathecal administration of cytarabine injection (preservative free preparation only) is indicated in the prophylaxis and treatment of meningeal leukemia. cytarabine injection is contraindicated in those patients who are hypersensitive to the drug.

United States - English - NLM (National Library of Medicine)

hospira, inc. - cytarabine (unii: 04079a1rdz) (cytarabine - unii:04079a1rdz) - cytarabine 20 mg in 1 ml - cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. it has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. intrathecal administration of cytarabine is indicated in the prophylaxis and treatment of meningeal leukemia. cytarabine injection is contraindicated in those patients who are hypersensitive to the drug.

United States - English - NLM (National Library of Medicine)

hospira, inc. - cytarabine (unii: 04079a1rdz) (cytarabine - unii:04079a1rdz) - cytarabine 20 mg in 1 ml - cytarabine injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. it has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. intrathecal administration of cytarabine injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia. cytarabine injection is contraindicated in those patients who are hypersensitive to the drug.

Canada - English - Health Canada

pharmascience inc - cytarabine - solution - 20mg - cytarabine 20mg - antineoplastic agents

Canada - English - Health Canada

pharmascience inc - cytarabine - solution - 100mg - cytarabine 100mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cytarabine 100 mg/ml - solution for injection - 100 mg/ml - active: cytarabine 100 mg/ml excipient: water for injection - cytarabine is indicated primarily for: · induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as · acute lymphocytic leukaemia · chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine. remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity. cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cytarabine 20 mg/ml - solution for injection - 20 mg/ml - active: cytarabine 20 mg/ml excipient: sodium chloride water for injection - cytarabine is indicated primarily for: · induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as · acute lymphocytic leukaemia · chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine. remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity. cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Malta - English - Medicines Authority

strides arcolab international limited unit 4, metro centre, tolpits lane, watford, hertfordshire, wd 189 ss, united kingdom - cytarabine - solution for infusion or injection - cytarabine 20 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

strides arcolab international limited unit 4, metro centre, tolpits lane, watford, hertfordshire, wd 189 ss, united kingdom - cytarabine - solution for infusion or injection - cytarabine 20 mg/ml - antineoplastic agents